Acrivon Therapeutics (ACRV) announced that Mansoor Raza Mirza, M.D., has been appointed Chief Medical Officer of the company, effective April 9. With the appointment of Dr. Mirza, the company’s current Chief Medical Officer, Jean-Marie Cuillerot, M.D., will depart the company on April 9.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Buy Rating Reaffirmed for Acrivon Therapeutics Amid Promising Endometrial Cancer Data and Strong Financial Position
- Acrivon Therapeutics price target lowered to $7 from $22 at JonesResearch
- Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer
- Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c)
- Acrivon Therapeutics Reports 2024 Financial Results and Progress